Neuromuscular Blockade Agents Reversal with Sugammadex Compared to Neostigmine in the Living Kidney Donors

Thuy Luu Quang; Huyen Nguyen Thi Thu; Kinh Nguyen Quoc; Ha Nguyen Thu; Dong Pham Van; Nguyen Le Bao Tien; Vo Van Thanh; Vu Thi Nga; Chu Dinh Toi

doi:10.3889/oamjms.2019.874

Neuromuscular Blockade Agents Reversal with Sugammadex Compared to Neostigmine in the Living Kidney Donors

Open Access Maced J Med Sci. 2019 Dec 20;7(24):4420-4425. doi: 10.3889/oamjms.2019.874. eCollection 2019 Dec 30.

Authors

Thuy Luu Quang¹, Huyen Nguyen Thi Thu¹, Kinh Nguyen Quoc¹, Ha Nguyen Thu², Dong Pham Van³, Nguyen Le Bao Tien⁴, Vo Van Thanh^{4

5}, Vu Thi Nga⁶, Chu Dinh Toi⁷

Affiliations

¹ Center for Anesthesia and Surgical Intensive Care, Viet Duc Hospital, Hanoi, Vietnam.
² Anesthesia & Intensive Care Departement, Hanoi Medical University, Hanoi, Vietnam.
³ Anesthesia and Pain Medicine, Cho Ray Hospital, Ho Chi Minh City, Viet Nam, Hanoi, Vietnam.
⁴ Institute of Orthopaedics and Trauma Surgery, Viet Duc Hospital, Hanoi, Vietnam.
⁵ Department of Surgery, Hanoi Medical University, Hanoi, Vietnam.
⁶ Institute for Research and Development, Duy Tan University, Danang, Vietnam.
⁷ Department of Human and Animaly Physiology, Faculty of Biology, Hanoi National University of Education, Hanoi, Vietnam.

Abstract

Backround: The reversation of NMBA (neuromuscular blocking agents) prevents numerous postoperative complications, increases quality of recovery and decreases the time, expenditure spending in hospital. The choice of medicine used to reverse NMBA depends considered as a key fators to gain the best outcome and to avoid the side effects.

Aim: To evaluate the postoperative effect on muscle relaxation reversal and side effects of sugammadex 2 mg/kg versus the combination of neostigmine and atropine sulfate in the living kidney donors.

Methods: A randomised controlled trial on 70 patients undergoing living kidney donation surgery were allocated to 2 groups. Patients in group I (SUGA) were reversed with sugammadex 2 mg/kg and in group II (NEO/ATR) with the combination of neostigmine and atropine sulfat.

Results: With 35 patients in each group, the study results showed that after 3 mintutes of reversal patients reaching TOF value ≥ 0.9 in group SUGA is 91.4%, after 5 minutes 100% of patients in group SUGA reached TOF value ≥ 0.9 . In group NEO/ATR after 3 minutes 28.6% patients reached TOF ≥ 0.9 and 40% patients reached TOF≥ 0.9 after 5 minutes. The difference in percentage of patients reaching TOF ≥ 0.9 after 3 minutes, 5 minutes of reversal between two groups is significant (p<0.05). After 10 minutes, 100% patients in both group got TOF ≥ 0.9. Time to exutubation of group SUGA was 249.43 ± 81.75 seconds and it was 456.29 ± 146.45 seconds in group NEO/ATR. Nausea, bradycardia, and increased phlegm production in group NEO/ATR was 22.9%; 28.5%; 25.7% respectively; while those side effects were not met in group SUGA, the difference was significant (p<0.05).

Conclusion: The muscle relaxation reversal effect of sugammadex was faster than that of neostigmine, the duration TOF ≥ 0.9 and the time to extubation was significantly faster. Sugammadex did not cause hemodynamic changes before and after muscle relaxation reversal, neostigmine resulted in the bradycardia, increased phlegm secreting and other side effects. The renal function after 24 hours postoperatively of two groups was similar.

Keywords: living kidney donors; muscle relaxants; sugammadex.